Published in Breast Cancer Res Treat on February 18, 2009
Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. Cancer Res (2009) 1.31
The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol (2010) 1.04
Tumor acquisition for biomarker research in lung cancer. Cancer Invest (2014) 0.75
Genomic analysis from tissue core biopsies: standard of care for the future? Breast Cancer Res Treat (2009) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer (2007) 4.74
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol (2005) 2.30
Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol (2005) 2.30
17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene (1996) 2.01
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res (2003) 1.94
Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res (2004) 1.76
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J (2002) 1.07
Differential expression of oestrogen regulated genes in breast cancer. Acta Oncol (1995) 0.95
RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation. J Biol Chem (2001) 0.92
The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer (1993) 0.89
The expression of interleukin-6 (IL-6), IL-6 receptor, and gp130-kilodalton glycoprotein in the rat decidua and a decidual cell line: regulation by 17beta-estradiol and prolactin. Endocrinology (1999) 0.86
Isolation and mapping of RAB2L, a human cDNA that encodes a protein homologous to RalGDS. Cytogenet Cell Genet (1996) 0.86
A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology (2007) 0.83
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res (2011) 3.25
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
BI-RADS for sonography: positive and negative predictive values of sonographic features. AJR Am J Roentgenol (2005) 2.57
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) (2009) 2.28
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
The Cancer Genome Atlas: clinical applications for breast cancer. Oncology (Williston Park) (2013) 2.19
US breast cancer mortality trends in young women according to race. Cancer (2014) 2.07
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 1.90
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol (2003) 1.83
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell (2003) 1.76
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res (2006) 1.74
Malignant lesions initially subjected to short-term mammographic follow-up. Radiology (2002) 1.73
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol (2005) 1.71
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Acoustic radiation force impulse imaging of the mechanical properties of arteries: in vivo and ex vivo results. Ultrasound Med Biol (2004) 1.68
Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol (2009) 1.67
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol (2009) 1.64
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther (2004) 1.63
Evaluation of a system for automatic detection of diabetic retinopathy from color fundus photographs in a large population of patients with diabetes: response to Abramoff et al. Diabetes Care (2008) 1.60
Unfolded protein response genes regulated by CED-1 are required for Caenorhabditis elegans innate immunity. Dev Cell (2008) 1.59
Computer-aided detection of amorphous calcifications. AJR Am J Roentgenol (2005) 1.59